Israeli researchers at a blood cancer conference in the US reported a lymphoma treatment that can achieve 100% survival rates ...

Gender and ethnic disparities in breast cancer and cardiovascular disease-related mortality in United States from 1999-2019: A retrospective analysis. This is an ASCO Meeting Abstract from the 2025 ...

A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved ...

“In our real-world experience, [Yescarta] in relapsed or refractory follicular lymphoma showed durable responses and a ...

In this phase 2 study, researchers sought to determine whether cytoreductive treatment with rituximab followed by epcoritamab would deepen responses and lower risk of cytokine release syndrome.

Factors associated with higher progression rates included double-hit/triple-hit lymphoma, high IPI status, and primary refractory disease. A recent study reveals critical insights on disease ...

Stage 3 Hodgkin’s lymphoma either indicates lymphoma in the lymph nodes both above and below a person’s diaphragm or in the lymph nodes above the diaphragm and in the spleen. Doctors may also refer to ...

In this analysis from the phase 3 S1826 study, researchers aimed to show the durability of the efficacy of nivolumab plus doxorubicin, vinblastine, and dacarbazine in classic Hodgkin lymphoma.

R 2 is the only second-line alternative to chemoimmunotherapy-based treatment for patients with relapsed/refractory ...